coronary artery disease

     

Select            
Trial Studied trt Control trt patientstagsROB Trial resultAll cause deathmyocardial infarction (fatal and non fatal)

anti-anginal drugs

nicorandil
Nishimura, 2009   nicorandilcontrolRisk of bias -
ranolazine
MARIZA, 2004     ranolazine 1000mgplaceboLow risk of bias -
RAN080, 2005     ranolazine 1000mgplaceboLow risk of bias -
CARISA 1000mg, 2004     ranolazine 1000mgplacebo (on top standard treatment)Low risk of bias negative
ERICA, 2006      NCTranolazine 1000mg + amlodipineplacebo + amlodipineLow risk of bias -

anticoagulant

not classified
MacMillan, 1960   anticoagulantno anticoagulant -
Borchegrevink, 1960   anticoagulantno anticoagulant -
Clausen, 1961   anticoagulantno anticoagulant -
Harvald, 1961   anticoagulantno anticoagulant -
Conrad, 1964     anticoagulantno anticoagulant -
Wasserman, 1966   anticoagulantno anticoagulant -
Loeliger, 1967   anticoagulantno anticoagulant -
Lovell, 1967   anticoagulantno anticoagulant -
Seaman, 1969     anticoagulantno anticoagulant -
Sorensen, 1969   anticoagulantno anticoagulant -
Meuwisse,, 1969   anticoagulantno anticoagulant -
Drapkin and Merskey, 1972     anticoagulantno anticoagulant -
Sixty Plus Reinfarction, 1980   coumarin congenersplaceboLow risk of bias -
ASPECT, 1994   nicoumalone or phenprocoumonplacebo -
Breddin, 1980   phenprocoumonplaceboLow risk of bias -
dicoumarol
Apenstrom and Korsan-Bengtsen, 1964   dicoumarolno anticoagulant -
wafarin
WARIS, 1990   warfarinplaceboLow risk of bias -

cell-based therapies

not classified
REVASC (Stewart), 2006     VEGF gene transfercontrol -
Ramshorst, 2009     autologous bone marrow–derived mononuclear cellsplaceboLow risk of bias -
Losordo, 2011      NCTCD34+ cellsplaceboExploratory -
Losordo, 2007      NCTstem cells CD34+placeboLow risk of bias -
VIVA (Henry), 2003     vascular endothelial growth factorplaceboLow risk of bias -
fibroblast growth factor
FIRST (Simons), 2002     fibroblast growth factorplaceboLow risk of bias -
AGENT-1 (Grines), 2002     fibroblast growth factor geneplacebo -
AGENT-2 (Grines), 2003     fibroblast growth factor geneplacebo -
AGENT-3    NCTfibroblast growth factor geneplacebo -
AGENT-4    NCTfibroblast growth factor geneplacebo -
AWARE    NCTfibroblast growth factor geneplaceboLow risk of bias -
AGENT 3 and 4 pooled   fibroblast growth factor geneplacebo -
gene therapy
EUROINJECT-ONE (Gyöngyösi), 2005     gene therapyplaceboLow risk of bias -

death and events prevention

aspirin
CDPA, 1976   aspirinplaceboLow risk of bias negative-30%
Cardiff I, 1974   aspirinplaceboLow risk of bias negative-26%
Cardiff II, 1979   aspirinplaceboLow risk of bias negative-17%
Vogel, 1979   aspirinplaceboLow risk of bias suggesting-32%
AMIS, 1980    NCTaspirinplaceboLow risk of bias suggesting11%
GAMIS, 1980   aspirinplaceboLow risk of bias negative-18%
PARIS, 1980   aspirinplaceboLow risk of bias negative-18%
JAMIS, 1999     aspirinplacebosuggesting18%
SAPAT, 1992   aspirinplaceboLow risk of bias suggesting
clopidogrel
CAPRIE, 1996     clopidogrelaspirinLow risk of bias -
ASCET    NCTclopidogrelaspirinRisk of bias negative
dipyridamol
Atlanta (Sbar), 1967   dipyridamolcontrolLow risk of bias negative
Becker, 1967   dipyridamolcontrolLow risk of bias negative
Wirecki, 1967   dipyridamolcontrolLow risk of bias negative
Igloe, 1970   dipyridamolplaceboLow risk of bias -
Zion, 1961   dipyridamolplaceboLow risk of bias -
Kinsella, 1962   dipyridamolplaceboLow risk of bias -
Leiberman, 1964   dipyridamolplaceboLow risk of bias -
Dewar, 1961   dipyridamolplaceboLow risk of bias -
Neumann, 1964   dipyridamolplaceboLow risk of bias -
Foulds, 1960   dipyridamolplaceboLow risk of bias -
PARIS, 1980   dipyridamol + aspirinplaceboLow risk of bias negative
PARIS-II, 1986   dipyridamol + aspirinplaceboLow risk of bias negative
PARIS, 1980   dipyridamol + aspirinaspirinLow risk of bias negative
ticlopidine
Berglund, 1985   ticlopidineplaceboLow risk of bias negative

Drug eluting stent

not classified
ISAR-CABG, 2011      NCTDESbare-metal stentRisk of bias suggesting9%-32%
TINOX, 2005     titanium-nitride-oxide coated stentbare-metal stentExploratory -
PAINT (sirolimus), 2009      NCTbiodegradable-polymerBMSRisk of bias -
EVOLVE, 2012      NCTbioabsorbable polymer EESeverolimus eluting stent -
Nordic-Baltic Bifurcation Study III, 2009    NCTkissing balloonno kissing balloonRisk of bias negative+Infini%-67%
NEVO RES-ELUTION I    NCTNevopaclitaxel eluting stentExploratory -
Costar II, 2008      NCTCoStar stentpaclitaxel eluting stentRisk of bias negative -31%47%
COSTAR II diabetic (sub group), 2008     CoStar stentpaclitaxel eluting stentExploratory negative
TRIAS-HR, 2008   Genous stentpaclitaxel eluting stentnegative-81%
BIOFREEDOM    NCTpolymer-free biolimus a9-eluting stentspaclitaxel eluting stentExploratory -
BBC ONE, 2008      NCTdouble stenting with PESsingle stentingnegative 100%211%
CACTUS , 2009     double stenting with SESsingle stentingRisk of bias negative-67%24%
Colombo, 2004     double stenting with SESsingle stentingExploratory negative200%
Ferenc, 2008     double stenting with SESsingle stentingExploratory negative-50%100%
NORDIC , 2006     double stenting with SESsingle stentingRisk of bias negative -40%96%
Pan, 2004     double stenting with SESsingle stentingExploratory negative7%-79%
ISAR TEST 2 (vs SES), 2009          NCTdual sirolimus, probucol eluting stentsirolimus eluting stentRisk of bias negative-11%17%
ISAR TEST 3 (PF), 2009     polymer free sirolimus stentsirolimus eluting stentnegative0%26%
ISAR TEST 3 (BP), 2009     sirolimus biodegradable polymersirolimus eluting stentnegative-25%
ISAR-TEST-4 (biodegradable polymer), 2009    NCTsirolimus biodegradable polymersirolimus eluting stentRisk of bias negative-1%4%
ISAR TEST 2 (vs ZES), 2009      NCTdual sirolimus, probucol eluting stentzotarolimus eluting stentRisk of bias -
ISAR TEST 5    NCTdual sirolimus, probucol eluting stentzotarolimus eluting stent click to display paper's table" >Risk of bias negative-18%
abciximab
Kim, 2010     abciximab-coated stentbare-metal stentExploratory -
biolimus eluting stent
LEADERS, 2008      NCTbiolimus eluting stentsirolimus eluting stentnegative-9%25%
candesartan
SYNTAX (unprotected left main sub group), 2009     DESCABGRisk of bias suggesting
dactinomycin eluting stent
ACTION, 2004   dactinomycin eluting stentbare-metal stentsuggesting-56%161%
drug-eluting stents
PASEO, 2009   drug-eluting stentsbare-metal stent -
DEDICATION, 2008      NCTdrug-eluting stentsbare-metal stentRisk of bias suggesting100%
GENIUS-STEMI, 2009     Genous stentbare-metal stentExploratory negative-Infini%
Boudriot, 2008   DESCABGExploratory negative-61%
FREEDOM, 2012      NCTPCI with drug-eluting stentsCABGRisk of bias negative
Hong, 2005     PCI withdrug-eluting stentsCABGRisk of bias -
everolimus eluting stent
FUTURE I, 2004     everolimus eluting stentbare-metal stentnegative+Infini%
FUTURE II, 2006   everolimus eluting stentbare-metal stentLow risk of bias -
SPIRIT I, 2005    NCTeverolimus eluting stentbare-metal stentExploratory negative+Infini%
BASKET-PROVE (EES), 2010   everolimus eluting stentbare-metal stentsuggesting-27%-36%
RESET, 2011    NCTeverolimus eluting stentsirolimus eluting stent -
PLATINUM, 2011      NCTeverolimus eluting stenteverolimus eluting stent -
SPIRIT II, 2006      NCTeverolimus eluting stentpaclitaxel eluting stentRisk of bias negative-65%
SPIRIT IV, 2010          NCTeverolimus eluting stentpaclitaxel eluting stentRisk of bias suggesting-17%-39%
SPIRIT III, 2008        NCTeverolimus eluting stentpaclitaxel eluting stentExploratory suggesting-2%-32%
COMPARE, 2009        NCTeverolimus eluting stentpaclitaxel eluting stentRisk of bias suggesting21%-48%
SPIRIT III (small vessel subgroup), 2009     everolimus eluting stentpaclitaxel eluting stentExploratory suggesting+Infini%+Infini%
SORT OUT IV, 2012      NCTeverolimus eluting stentsirolimus eluting stentRisk of bias -
ISAR-TEST 4 (EES vs SES)     everolimus eluting stentsirolimus eluting stentsuggesting
paclitaxel
ISAR-DESIRE (PES vs PTCA), 2005     paclitaxel eluting stentballoon angioplastysuggesting-67%+Infini%
TAXUS I, 2003     paclitaxel eluting stentbare-metal stentLow risk of bias negative
TAXUS II, 2003      NCTpaclitaxel eluting stentbare-metal stentLow risk of bias suggesting-100%139%
TAXUS IV, 2004        NCTpaclitaxel eluting stentbare-metal stentLow risk of bias suggesting11%146%
SCORE, 2004   paclitaxel eluting stentbare-metal stentsuggesting +Infini%+Infini%
TAXUS V (all patients), 2005    NCTpaclitaxel eluting stentbare-metal stentLow risk of bias suggesting-11%17%
TAXUS VI, 2005        NCTpaclitaxel eluting stentbare-metal stentLow risk of bias suggesting-100%4%
PASSION, 2006     paclitaxel eluting stentbare-metal stentRisk of bias negative-30%-16%
HAAMU-STENT, 2006   paclitaxel eluting stentbare-metal stentExploratory negative114%
Erglis, 2007     paclitaxel eluting stentbare-metal stentsuggesting-6%-33%
HORIZONS-AMI Stent, 2008     paclitaxel eluting stentbare-metal stentsuggesting1%-18%
TAXUS II (diabetics), 2003     paclitaxel eluting stentbare-metal stentLow risk of bias suggesting
TAXUS IV (diabetics), 2005      NCTpaclitaxel eluting stentbare-metal stentLow risk of bias suggesting
TAXUS V (diabetics), 2005   paclitaxel eluting stentbare-metal stentLow risk of bias suggesting
TAXUS VI (diabetics), 2005      NCTpaclitaxel eluting stentbare-metal stentLow risk of bias suggesting
SOS, 2008        NCTpaclitaxel eluting stentbare-metal stentExploratory suggesting138%-52%
TAXUS V small vessels sub groups   paclitaxel eluting stentbare-metal stent -
ASPECT, 2003      NCTpaclitaxel, non-polymeric eluting stentbare-metal stentLow risk of bias suggesting+Infini%
ELUTES, 2004     paclitaxel, non-polymeric eluting stentbare-metal stentnegative+Infini%
DELIVER, 2004   paclitaxel, non-polymeric eluting stentbare-metal stentRisk of bias negative-75%98%
PATENCY, 2002   paclitaxel, non-polymeric eluting stentbare-metal stentLow risk of bias negative-100%
TAXUS V ISR, 2006      NCTpaclitaxel eluting balloonbrachytherapyRisk of bias -
SYNTAX, 2009          NCTpaclitaxel eluting stentCABGRisk of bias suggesting 25%47%
ISAR-test (diabetics), 2006     paclitaxel eluting stentsirolimus eluting stentRisk of bias -
sirolimus eluting stent
ISAR-DESIRE (SES vs PTCA), 2005     sirolimus eluting stentballoon angioplastysuggesting-33%+Infini%
Kochiadakis, 2007     sirolimus eluting stentbare-metal stentExploratory -
RAVEL, 2002      NCTsirolimus eluting stentbare-metal stentLow risk of bias suggesting-2%-21%
SIRIUS, 2003            NCTsirolimus eluting stentbare-metal stentLow risk of bias suggesting64%-13%
C-SIRIUS, 2004      NCTsirolimus eluting stentbare-metal stentLow risk of bias